导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -3.91% | 3187/4773 |
| 近一周 | -2.57% | 2574/5462 |
| 近一月 | -3.47% | 1771/5421 |
| 近一季 | -10.16% | 3418/5209 |
| 近半年 | -10.83% | 3686/4920 |
| 近一年 | 2.23% | 2169/4366 |
| 近两年 | 72.62% | 927/2954 |
| 近三年 | 33.81% | 905/2253 |
| 成立以来 | 125.15% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
0.23% 1600/4961 |
11.26% 2354/5312 |
- - |
- - |
| 2025 | 35.48% 986/4813 |
7.06% 527/3635 |
5.23% 625/4076 |
16.27% 2680/4524 |
3.43% 673/4813 |
| 2024 | 5.51% 1831/3463 |
-8.42% 2225/2808 |
-5.84% 1807/3014 |
14.37% 1988/3129 |
6.99% 468/3463 |
| 2023 | -1.30% 500/2656 |
9.23% 420/2280 |
-2.60% 616/2385 |
-4.51% 1156/2515 |
-2.85% 544/2655 |
| 2022 | -16.25% 465/2207 |
-15.16% 1025/1919 |
10.31% 264/2016 |
-10.57% 427/2113 |
0.05% 1546/2208 |
| 2021 | 25.45% 110/1822 |
-2.22% 601/1255 |
13.08% 296/1330 |
5.06% 296/1466 |
7.99% 169/1822 |
| 2020 | 38.57% 353/1250 |
-1.01% 198/1028 |
21.07% 249/1067 |
9.86% 607/1164 |
5.25% 795/1184 |
| 2019 | 36.62% 354/1092 |
33.26% 139/739 |
-5.25% 456/788 |
0.72% 477/850 |
7.43% 434/918 |
| 2018 | -23.70% 293/834 |
- - |
-12.94% 420/631 |
-5.83% 382/660 |
-7.22% 59/682 |
| 2017 | -1.31% 495/714 |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 创金合信中证1000指数增强A VS. 长安沪深300非周期A(740101) |